Olodaterol
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
Olodaterol: From Chronic Obstructive Pulmonary Disease to Bronchitis
One-Sentence Summary
Olodaterol is an inhaled long-acting beta2-agonist (LABA), originally used for the maintenance treatment of chronic obstructive pulmonary disease (COPD). The TxGNN model predicts it may be effective for bronchitis, but this prediction rests on overlap with the approved COPD indication, and no clinical trials and 2 publications (both about COPD, not bronchitis specifically) are currently available.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Chronic obstructive pulmonary disease (COPD); COPD, severe early onset |
| Predicted New Indication | Bronchitis |
| TxGNN Prediction Score | 99.84% |
| Evidence Level | L4 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. Based on known information, olodaterol is a once-daily long-acting beta2-adrenoceptor agonist that relaxes airway smooth muscle and produces sustained bronchodilation. Its efficacy in COPD has been established.
Chronic bronchitis is a component of COPD, so the link between the original and predicted indication is mostly a matter of disease classification overlap rather than a new pharmacological finding. The two retrieved publications are a COPD guideline and a COPD drug review. Neither provides bronchitis-specific data.
The high TxGNN score most likely reflects the closeness of bronchitis to COPD in the disease ontology, not new repurposing evidence.
Clinical Trial Evidence
Currently no related clinical trials registered for bronchitis.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 27354040 | 2016 | Review | Am J Health Syst Pharm | Reviews pharmacology, pharmacokinetics, efficacy and safety of once-daily olodaterol in COPD |
| 25515181 | 2015 | Review (guideline) | Basic Clin Pharmacol Toxicol | Finnish national guideline on diagnosis and pharmacotherapy of stable COPD; no bronchitis-specific data |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN15890P | SPIOLTO® RESPIMAT® Re-usable Solution for Inhalation 2.5 mcg / 2.5 mcg | Solution | Not stated in the available registration data |
Safety Considerations
Drug Interactions: 100 interactions were identified in the interaction screen. The 20 listed in the data compiled for this report are all rated Moderate, including:
- Sympathomimetics and stimulants: epinephrine (including ophthalmic and topical forms), ephedrine (including nasal), isometheptene, phentermine, diethylpropion, fenfluramine
- Drugs affecting QT interval: clarithromycin, cisapride, dolasetron, granisetron, palonosetron
- Glucose-lowering and related agents: canagliflozin, ertugliflozin, albiglutide, semaglutide
- Others: famotidine, loperamide
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The bronchitis prediction is driven mainly by its overlap with COPD, which is already the approved indication. No bronchitis-specific trials exist and the two publications address COPD only, so this is not a true repurposing signal.
To proceed, the following is needed:
- Bronchitis-specific clinical or observational data (for example, chronic bronchitis subgroup analyses from the existing COPD trials)
- Clarification of whether the prediction represents a genuinely new use or simply a restatement of the COPD indication
- Mechanism of action data
- Package insert warnings and contraindications from the HSA, needed for safety screening
- The approved indication text for the Singapore registration
Other predicted indications for reference:
- Obstructive lung disease (score 99.57%, evidence level L1, Proceed with Guardrails): essentially the approved COPD indication, supported by multiple completed Phase 3 RCTs. This is an on-label confirmation, not a new repurposing opportunity.
- Interstitial emphysema, compensatory emphysema, hyperlucent lung, tracheal stenosis, CD8alpha-related respiratory infection susceptibility, congenital lobar emphysema, tracheal calcification, respiratory malformation: no supporting clinical evidence and no clear mechanistic rationale (Hold).
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.